Chronic myelomonocytic leukemia represents a distinct myelodysplastic
syndrome in which an excess of monocytes is observed both in the blood
and bone marrow of the patients. Whereas diagnosis is relatively easy
, therapeutic design and efficacy is difficult and no treatment has to
date provided complete or significant partial response. In vitro data
suggest that the growth and differentiation of myelomonocytic progeni
tors may be altered inasmuch as monocytic or granule-macrophagic colon
ies show spontaneous growth. Different entities may be observed: the c
hildhood form, Juvenile Chronic Myelomonocytic Leukemia (JCML) shows i
n vitro a typical pattern with constitutive growth of only macrophagic
colonies and hypersensitivity to GM-CSF; in the adult form at least t
wo patterns may be observed one close to the JCML form and one more he
terogeneous with absence of GM-CSF sensitivity and spontaneous growth
of both CFU-GM and CFU-M colonies. Chemotherapy reduces all myeloid co
lonies in vitro whereas retinoic acid has a selective effect on monocy
tic colonies with a concomitant increase of CFU-G colonies forwarding
an explanation for the correction of pancytopenia observed in some pat
ients. Recent analysis of altered molecular pathways in this disease s
uggest a common disruption of intracelleular signalling pathways namel
y the Ras pathway and targetting for drugs with may selectively contro
l or inhibit a constitutive activation may forward novel therapeutic p
erspectives.